Get the Stockscreener App
13.91
6.26%
0.82
After Hours:
13.88
-0.03
-0.22%
Amneal Pharmaceuticals Inc stock is traded at $13.91, with a volume of 1.85M.
It is up +6.26% in the last 24 hours and up +11.91% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$13.09
Open:
$13.47
24h Volume:
1.85M
Relative Volume:
0.74
Market Cap:
$4.44B
Revenue:
$3.02B
Net Income/Loss:
$127.93M
P/E Ratio:
62.86
EPS:
0.2213
Net Cash Flow:
$225.64M
1W Performance:
+10.93%
1M Performance:
+11.91%
6M Performance:
+40.22%
1Y Performance:
+88.99%
1-Day Range:
$13.34
$13.92
1-Week Range:
$12.30
$13.92
52-Week Range:
$7.02
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
13.91 | 4.44B | 3.02B | 127.93M | 225.64M | 0.2213 |
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 56.30B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
122.38 | 51.46B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.75 | 43.42B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.40 | 37.73B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
588.38 | 25.79B | 3.18B | 1.33B | 1.04B | 27.90 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | UBS | Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Amneal rated Buy in new research coverage at UBS as growth pipeline expands (AMRX:NASDAQ) - Seeking Alpha
Healthcare Stocks Rise as Strait Reopening Cuts Costs | 2026 Market UpdateNews and Statistics - IndexBox
Here's how AMRX is tapping GLP-1 demand through manufacturing - MSN
Bruker, Amneal, Amphastar Pharmaceuticals, Dentsply Sirona, and PacBio Stocks Trade Up, What You Need To Know - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) Upgraded to "Strong-Buy" at UBS Group - MarketBeat
UBS initiates coverage of Amneal Pharmaceuticals (AMRX) with buy recommendation - MSN
AMRX: 3 growth drivers behind Amneal's 2026 outlook - MSN
Market movers: Netflix, American Airlines, United Airlines, Amneal Pharmaceuticals... - Proactive financial news
Amneal shares rise after UBS initiates at Buy, cites “best-in-group” growth in specialty pharma - Yahoo! Finance Canada
UBS initiates Amneal Pharmaceuticals stock with buy rating at $19 - Investing.com
Amneal denied summary judgment against US states’ antitrust case over Phenytoin - MLex
Amneal Trims But Can't Nix AGs' Drug Price-Fixing Suit - Law360
Judge Dismisses Benzene Suit For Failure To State A Claim But Grants Leave To Amend - Mealey's
92,010 Shares in Amneal Pharmaceuticals, Inc. $AMRX Purchased by Tudor Investment Corp ET AL - MarketBeat
Is AMRX stock undervalued? Sales multiple, target, upside - MSN
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. - Yahoo Finance
Amneal launches generic bimatoprost 0.01% to US market - Eyes On Eyecare
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Significant Decrease in Short Interest - MarketBeat
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced the official launch of Albuterol Sulfate and Beclomethasone Dipropionate HFA inhalation aerosols in the U.S. market. - Exchange Bitget
Institution Moves: Is Amneal Pharmaceuticals Inc a strong candidate for buy and hold2026 Price Momentum & Low Risk High Reward Ideas - baoquankhu1.vn
Aug Fed Impact: Is Amneal Pharmaceuticals Inc in a long term uptrend2026 Volatility Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Should Amneal’s New Generic Glaucoma Launch Shape How AMRX Investors View Its Specialty Strategy? - Sahm
Fund Flows: Is Amneal Pharmaceuticals Inc forming a double bottomEarnings Overview Summary & Fast Momentum Entry Tips - baoquankhu1.vn
AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook - qz.com
Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing - qz.com
Is AMRX Stock Undervalued? Sales Multiple, Target, Upside - qz.com
Why Amneal Pharmaceuticals (AMRX) is a top growth stock for the long term - MSN
AMRX: 3 Key Factors Fueling Amneal's Projections for 2026 - Bitget
Here's the way AMRX is leveraging the demand for GLP-1 via its manufacturing operations - Bitget
Why Amneal Pharmaceuticals (AMRX) Stands Out as a Leading Long-Term Growth Stock - Bitget
FOCUS-Patients scramble to find estrogen patches as shortage worsens after US FDA champions use - Sahm
Is It Time To Reassess Amneal Pharmaceuticals (AMRX) After Its Strong Multi Year Share Price Run? - Sahm
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Launching Its New Glaucoma Generic - Yahoo Finance
FDA sends latest Untitled Letters to Amneal, BioCorRx over brochures, websites - Medical Marketing and Media
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01% - Bitget
Amneal rolls out generic glaucoma eye drop in a $719M U.S. market - Stock Titan
AMRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Volatility Watch: Whats the fair value of Amneal Pharmaceuticals Inc stock2026 Historical Comparison & Proven Capital Preservation Tips - baoquankhu1.vn
Amneal marks Parkinson's Awareness Month, $2M donation - Post Register
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
6.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):